Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Innoviva Inc    INVA

INNOVIVA INC (INVA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/18/2018 04/19/2018 04/20/2018 04/23/2018 04/24/2018 Date
15.9(c) 16.23(c) 16.14(c) 15.95(c) 15.79 Last
876 519 802 716 520 335 545 955 1 340 898 Volume
-0.44% +2.08% -0.55% -1.18% -1.00% Change
More quotes
Financials (USD)
Sales 2018 287 M
EBIT 2018 265 M
Net income 2018 256 M
Debt 2018 324 M
Yield 2018 2,09%
Sales 2019 322 M
EBIT 2019 299 M
Net income 2019 306 M
Debt 2019 114 M
Yield 2019 -
P/E ratio 2018 7,09
P/E ratio 2019 5,94
EV / Sales2018 6,81x
EV / Sales2019 5,43x
Capitalization 1 632 M
More Financials
Company
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals.Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone... 
Sector
Pharmaceuticals
Calendar
04/24 | 03:00pmShareholder meeting
More about the company
Surperformance© ratings of Innoviva Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on INNOVIVA INC
04/24INNOVIVA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/24GlaxoSmithKline's Trelegy Ellipta Gets Expanded Indication From FDA
DJ
04/21INNOVIVA : Theravance Biopharma Highlights Landmark IMPACT Study Published in NE..
AQ
04/20INNOVIVA : Landmark IMPACT Study Published in NEJM Shows Significant Benefits of..
AQ
04/10XL : Analysts See $0.97 EPS for XL Group Ltd (XL); Innoviva (INVA) Shorts Raised..
AQ
03/14GLAXOSMITHKLINE : GSK announces positive EU approval for labelling update to Rel..
AQ
03/09GLAXOSMITHKLINE : s Relvar Ellipta gets updated label in EU
AQ
03/09INNOVIVA : GSK Announces Positive EU Approval for Labelling Update to Relvar Ell..
AQ
02/28INNOVIVA, INC. : Other Events (form 8-K)
AQ
02/23INNOVIVA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
More news
Sector news : Pharmaceuticals - NEC
04/24EXCLUSIVE : Shire, Takeda reach breakthrough in deal talks - sources
RE
04/24EXCLUSIVE - SHIRE, TAKEDA REACH BREA : sources
RE
04/24Monsanto develops product to deactivate controversial farm chemical
RE
04/24GlaxoSmithKline's Trelegy Ellipta Gets Expanded Indication From FDA
DJ
04/24LONDON MARKETS : FTSE 100 Scores 6th Win In A Row As Oil Shares, Shire Rally
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/24$THRX New Form 8-K for Innoviva, Inc. From our Stock News Alerts App 
04/22Innoviva $INVA Lowered to Buy at BidaskClub  
04/20GlaxoSmithKline, Innoviva: Landmark IMPACT study shows significant benefits o..
1
04/20Innoviva $INVA Earns Media Sentiment Score of 0.21  
04/20$INVA: Innoviva and GlaxoSmithKline (GSK) landmark IMPACT study published in .. 
More tweets
Qtime:81
News from SeekingAlpha
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/17ADJUSTED PRICE TARGETS FOR THIS BIO- : More Than 20% Upside 
04/10INNOVIVA INC. : Buy This Small-Cap Biopharma Royalty Holding Company With 50% Up.. 
03/08BY THE NUMBERS : Profitable Stocks With Reasonable Valuations And Rising Earning.. 
02/25WEEK 9 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
Chart INNOVIVA INC
Duration : Period :
Innoviva Inc Technical Analysis Chart | INVA | US45781M1018 | 4-Traders
Technical analysis trends INNOVIVA INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 15,0 $
Spread / Average Target -6,0%
EPS Revisions
Managers
NameTitle
Eric d'Esparbes CEO, Chief Financial Officer & Senior VP
William H. Waltrip Chairman
Theodore J. Witek Chief Scientific Officer & Senior Vice President
Catherine J. Friedman Independent Director
Paul Pepe Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INNOVIVA INC12.40%1 632
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571